Nutriband Inc. income statement
In fiscal 2026, Nutriband Inc. reported revenue of $2.0m, down 4.8% on the year before, operating income of −$8.3m (a -408.4% margin) and net income of −$8.2m, or −$2.58 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2019Jan 2019 | 2020Jan 2020 | 2021Jan 2021 | 2022Jan 2022 | 2023Jan 2023 | 2024Jan 2024 | 2025Jan 2025 | 2026Jan 2026 | LTMJul 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Cost of revenue | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Gross profit | −0 | −0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Research and development | — | — | — | 0 | 1 | 2 | 3 | 2 | 1 |
| Selling, general and administrative | 3 | 2 | 3 | 4 | 4 | 4 | 4 | 7 | 6 |
| Operating income | −3 | −2 | −3 | −6 | −4 | −5 | −10 | −8 | −7 |
| Interest expense | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −3 | −3 | −3 | −6 | −4 | −5 | −10 | −8 | −7 |
| Net income | −3 | −3 | −3 | −6 | −4 | −5 | −10 | −8 | −7 |
| Diluted EPS | −$0.62 | −$0.50 | −$0.51 | −$0.80 | −$0.53 | −$0.69 | −$0.99 | −$2.58 | −$0.57 |
| Diluted shares (average) | 5m | 5m | 6m | 8m | 8m | 8m | 11m | 12m | 12m |
| EBITDA | −3 | −2 | −2 | −6 | −4 | −5 | −10 | −8 | −7 |
| Quarter | 2025 Q3Oct 2024 | 2025 Q4Jan 2025 | 2026 Q1Apr 2025 | 2026 Q2Jul 2025 | 2026 Q3Oct 2025 | 2026 Q4Jan 2026 | 2027 Q1Apr 2026 | 2027 Q2Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 646 | 642 | 667 | 622 | 346 | 401 | 433 | 438 |
| Cost of revenue | 455 | 356 | 415 | 466 | 278 | 312 | 237 | 256 |
| Gross profit | 191 | 286 | 252 | 157 | 69 | 89 | 197 | 182 |
| Research and development | 881 | 490 | 683 | 563 | 457 | 188 | 247 | 322 |
| Selling, general and administrative | 737 | 1,760 | 982 | 1,598 | 3,492 | 922 | 1,204 | 750 |
| Operating income | −1,427 | −5,559 | −1,413 | −2,003 | −3,880 | −1,021 | −1,254 | −891 |
| Interest expense | 4 | 4 | 3 | 6 | 6 | 5 | 5 | 5 |
| Income before tax | −1,363 | −5,516 | −1,389 | −2,000 | −3,872 | −968 | −1,242 | −881 |
| Net income | −1,363 | −5,516 | −1,389 | −2,000 | −3,872 | −968 | −1,242 | −881 |
| Diluted EPS | −$0.12 | −$0.51 | −$0.12 | −$2.12 | −$0.32 | −$0.04 | −$0.10 | −$0.07 |
| EBITDA | −1,354 | −5,486 | −1,356 | −1,946 | −3,837 | −985 | −1,220 | −857 |
Compare with peers
- Lipocine Inc. income statement
- China SXT Pharmaceuticals, Inc. income statement
- 60 Degrees Pharmaceuticals, Inc. income statement
- Eyepoint, Inc. income statement
- Scienture Holdings, Inc. income statement
Head to head: LPCN vs NTRBNTRB vs SXTCNTRB vs SXTPEYPT vs NTRB
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies